If cleared by the FDA, the AGN1 LOEP SV kit would represent a breakthrough treatment for stable vertebral compression fractures.
The kit contains a proprietary, calcium-based, resorbable, tri-phasic implant material that is uniquely formulated to couple the pace of resorption to bone formation so that treated vertebrae are immediately, substantially and durably protected.
A surgical kit containing the material is already approved in Europe for larger volume applications.
The FDA Breakthrough Devices Program is intended to expedite the development and review of devices that are either novel or have the potential to benefit patients with life-threatening or debilitating conditions.
By accelerating the process of development and review, it is hoped that clinicians and patients will have faster access to devices that can improve the quality of care.
Spine fractures afflict more than a half a million patients in the US every year.
These fractures often cause debilitating pain and can lead to a downward spiral of reduced mobility, independence and a greater likelihood of additional fractures.
Given the aging population in the US and globally, this problem is expected to become more common over time.
Other surgical approaches to address painful fractures in the spine exist but can have downsides, including the potential for some treatments to increase fracture risk in adjacent vertebral bodies.
The AGN1 LOEP SV Kit is an investigational device intended to minimally-invasively treat painful but stable vertebral compression fractures that are often caused by bone loss associated with osteoporosis.
The kit contains all of the instruments and components necessary to prepare the fractured vertebral body for injection with the proprietary, calcium-based, osteoconductive, tri-phasic implant material.
The implant material is already approved in Europe to treat bone loss in higher volume applications at other anatomical sites.
AgNovos Healthcare is a medical technology company specializing in minimally-invasive surgical procedures to address the local effects of bone disease.
The company's first product, the OSSURE Local Osteo-enhancement Procedure kit is CE-marked to treat local bone loss. The company is privately-held and headquartered in New York City, with manufacturing, research and development and corporate support services located in Rockville, Maryland.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial